8EB2
Structure of HLA-A*02:01 in complex with NY-ESO-1 peptide and PA2.1 Fab
Summary for 8EB2
Entry DOI | 10.2210/pdb8eb2/pdb |
Descriptor | HLA-A*02:01 alpha chain, Beta-2-microglobulin, NY-ESO-1 peptide, ... (5 entities in total) |
Functional Keywords | complex, fab, antibody, mhc class i, immune system |
Biological source | Homo sapiens (human) More |
Total number of polymer chains | 15 |
Total formula weight | 277758.34 |
Authors | Jette, C.A.,West, A.P. (deposition date: 2022-08-30, release date: 2022-11-30, Last modification date: 2024-01-31) |
Primary citation | Mock, J.Y.,Winters, A.,Riley, T.P.,Bruno, R.,Naradikian, M.S.,Sharma, S.,Jette, C.A.,Elshimali, R.,Gahrs, C.,Toledo-Warshaviak, D.,West Jr., A.P.,Kamb, A.,Hamburger, A.E. HLA-A∗02-gated safety switch for cancer therapy has exquisite specificity for its allelic target antigen. Mol Ther Oncolytics, 27:157-166, 2022 Cited by PubMed Abstract: Innovative cell-based therapies are important new weapons in the fight against difficult-to-treat cancers. One promising strategy involves cell therapies equipped with multiple receptors to integrate signals from more than one antigen. We developed a specific embodiment of this approach called Tmod, a two-receptor system that combines activating and inhibitory inputs to distinguish between tumor and normal cells. The selectivity of Tmod is enforced by the inhibitory receptor (blocker) that recognizes an antigen, such as an HLA allele, whose expression is absent from tumors because of loss of heterozygosity. Although unwanted cross-reactivity of the blocker likely reduces efficacy rather than safety, it is important to verify the blocker's specificity. We have tested an A∗02-directed blocker derived from the PA2.1 mouse antibody as a safety mechanism paired with a mesothelin-specific activating CAR in our Tmod construct. We solved the crystal structure of humanized PA2.1 Fab in complex with HLA-A∗02 to determine its binding epitope, which was used to bioinformatically select specific class I HLA alleles to test the blocker's functional specificity . We found that this A∗02-directed blocker is highly specific for its cognate antigen, with only one cross-reactive allele (A∗69) capable of triggering comparable function. PubMed: 36381658DOI: 10.1016/j.omto.2022.09.010 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.9 Å) |
Structure validation
Download full validation report